Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan 26;14(1):e21650.
doi: 10.7759/cureus.21650. eCollection 2022 Jan.

Sibutramine-Induced Nonischemic Cardiomyopathy

Affiliations
Case Reports

Sibutramine-Induced Nonischemic Cardiomyopathy

Meet S Shah et al. Cureus. .

Abstract

Within the past 20 years, the global pandemic of obesity and associated life-threatening comorbidities significantly promoted the development and intervention of anti-obesity pharmacotherapy. Sibutramine hydrochloride monohydrate, formerly sold under the brand name Meridia and Reductil among others, is an anti-obesity, selective serotonin, and norepinephrine reuptake inhibitor drug that suppresses appetite and reduces body weight in conjunction with lifestyle modifications. However, since 2010, it has been discontinued in a majority of countries such as the United States and European Union due to an associated increase in cardiovascular events such as hypertension, tachycardia, arrhythmias, and myocardial infarction. Thus, this article illustrates a case of sibutramine-induced nonischemic cardiomyopathy, including details of evaluation, management, and monitoring of patient progress. Herein, we present a case report of a 19-year-old male with no prior medical conditions who presented to the emergency department after being found in a state of cardiac arrest (pulseless ventricular fibrillation) with consequent intubation in the field. Upon admission, cardiac catheterization and echocardiography revealed patent coronary arteries with a reduced ejection fraction of approximately 15%-20%. Acute systolic heart failure secondary to nonischemic cardiomyopathy was treated with standard medical management. In addition, due to continued episodes of non-sustained ventricular tachycardia, the patient also underwent a subcutaneous implantable cardioverter-defibrillator (ICD) placement.

Keywords: anti-obesity; cardiomyopathy; dietary supplement; nonischemic; sibutramine.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Coronary angiogram
Coronary arteries are patent, without any morphological abnormalities. A: Right coronary artery (RCA). B: Left main coronary artery and left anterior descending (LAD) artery. C: Left anterior descending artery and left circumflex (LCX) artery. D: Left anterior descending artery and left circumflex artery.
Figure 2
Figure 2. Electrocardiogram
ECG tracing in the hospital shows a normal rate, sinus rhythm, and premature ventricular contraction.

References

    1. Sibutramine effects on central mechanisms regulating energy homeostasis. Araújo JR, Martel F. Curr Neuropharmacol. 2012;10:49–52. - PMC - PubMed
    1. Sibutramine on cardiovascular outcome. Scheen AJ. Diabetes Care. 2011;34 Suppl 2:0–9. - PMC - PubMed
    1. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. James WP, Caterson ID, Coutinho W, et al. N Engl J Med. 2010;363:905–917. - PubMed
    1. A case report on sibutramine induced cardiomyopathy. Ibrahim O, Maskan O, Liang T, Hassan H, Rahman M. https://ispub.com/IJC/10/2/14249 Int J Cardiol. 2012;10
    1. Characteristics, treatments, and outcomes of hospitalized heart failure patients stratified by etiologies of cardiomyopathy. Shore S, Grau-Sepulveda MV, Bhatt DL, et al. JACC Heart Fail. 2015;3:906–916. - PubMed

Publication types

LinkOut - more resources